Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science · 2004 · 1.8K citations

Medicine, Oncology, Pharmacology +14

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus et al. · New England Journal of Medicine · 2010 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +10

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian Druker, François Guilhot et al. · Blood · 2008 · 637 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +6